The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway-Reference-Cited by-同舟云学术

The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway

Published:2020-04-01 Issue:3 Volume:35 Page:190-198
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Fantini Massimo¹,David Justin M.¹,Annunziata Christina M.²,Morelli Maria Pia²,Arlen Phillip M.¹,Tsang Kwong Y.¹

Affiliation:

1. Precision Biologics, Inc., Bethesda, Maryland.

2. Women's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2019.3141

Reference46 articles.

1. Cancer immunotherapy: harnessing the immune system to battle cancer

2. Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression

3. The blockade of immune checkpoints in cancer immunotherapy

4. Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

5. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells;Expert Review of Vaccines;2024-09

2. CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells;Current Cancer Drug Targets;2024-07

3. Characteristics of Carcinoembryonic Antigen-Related Cell Adhesion Molecules and Their Relationship to Cancer;Molecular Cancer Therapeutics;2024-03-15

4. The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer;Frontiers in Immunology;2023-11-24

5. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground;Biomedicine & Pharmacotherapy;2023-09